Tecogen Inc. filings document the regulatory record for a Delaware operating company with common stock listed on NYSE American under TGEN. The company's Form 8-K reports furnish earnings releases, supplemental presentation materials, Regulation FD product communications, advisory agreement matters, and other events tied to its clean energy products and chiller applications.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Other disclosures address related-person transactions, promissory note matters, capital structure, risk factors referenced in periodic reports, and governance controls around company agreements and public communications.
Tecogen Inc. is holding its 2026 Annual Meeting of Stockholders on June 5, 2026 at 1:00 p.m. in North Billerica, Massachusetts. Stockholders of record as of April 8, 2026, when 29,905,229 common shares were outstanding, may vote.
They will elect seven directors, ratify Wolf & Company, P.C. as independent auditor, and cast non-binding advisory votes on 2025 executive compensation and on how often to hold future say‑on‑pay votes, with the Board recommending “three years” for frequency. The proxy also details board committees, executive and director pay, ownership of large shareholders and insiders, and equity compensation plans.
TECOGEN INC. director Susan B. Hirsch reported an open-market purchase of 5,000 shares of the company’s Common Stock. The shares were bought at a price of $3.73 per share. After this transaction, she directly owns 265,416 Common Stock shares.
Tecogen Inc. reported that it has extended its Advisory Agreement with Mr. John N. Hatsopoulos. The agreement, originally dated January 18, 2018 and previously amended in 2019 and 2023, will now run through March 31, 2028. The company’s Board of Directors approved the extension by Unanimous Written Consent on April 7, 2026, and the letter agreement documenting this extension is filed as an exhibit.
TECOGEN INC. director Susan B. Hirsch reported an open-market purchase of 10,000 shares of common stock at $2.54 per share. Following this buy, she directly holds 260,416 common shares, increasing her personal stake in the company.
Tecogen Inc. director Earl Lewis reported an open-market purchase of 5,000 shares of Tecogen common stock at an average price of $2.5192 per share. The filing shows that, following this transaction, Lewis directly or through a trust associated with him holds 1,011,006 Tecogen shares.
TECOGEN INC. director Earl Lewis reported an open-market purchase of the company’s common stock through a trust. The trust acquired 5,000 shares at an average price of $2.8817 per share on March 26, 2026. Following this transaction, holdings associated with Lewis total 1,006,006 shares of common stock, indicating a relatively small incremental increase to an already substantial position.
Tecogen Inc. reported that its General Counsel and Secretary, John Kimball Whiting IV, made an open-market purchase of Common Stock. He bought 10,000 shares at $2.38 per share and now directly owns 22,612 shares. This filing highlights an increase in his personal stake in the company.
TECOGEN INC. Chief Accounting Officer Roger P. Deschenes bought additional company stock in the open market. On March 20, 2026, he purchased 10,000 shares of common stock at $2.23 per share. Following this transaction, he directly holds 52,962 shares of Tecogen common stock.
TECOGEN INC. Chief Executive Officer and Chief Financial Officer Rangesh Abinand reported an open-market purchase of 3,000 shares of common stock on 2026-03-20 at a price of $2.298 per share. Following this transaction, his directly reported holdings increased to 67,193 shares of common stock.
According to a footnote, 2,500 of the purchased shares were acquired by Rangesh Abinand and 500 shares were acquired by his daughter, all reported in this Form 4. The transaction is classified as a non-derivative, open-market purchase.
TECOGEN INC. director John Hatsopoulos exercised stock options to acquire 50,000 shares of Common Stock at $0.88 per share under a Stock Option Agreement dated September 20, 2023. Following the exercise, he directly owns 1,038,951 shares of Tecogen Common Stock, indicating an exercise-and-hold transaction with no same-day share sale disclosed.